Kernel is a neurotechnology company developing non-invasive brain-computer interface (BCI) technology. Founded in 2016 by Bryan Johnson (founder of Braintree and payments company Block), Kernel's mission is to develop advanced neural interfaces to understand, honor, and enhance the human brain.
The company focuses on non-invasive approaches that can be used without surgery, making brain computing accessible to a broader population. Kernel's technology aims to enable applications in cognitive enhancement, medical monitoring, and human-computer interaction.
- Founded: 2016
- Headquarters: Los Angeles, California, USA
- Founder/CEO: Bryan Johnson
- Funding: Over $110 million (Series C)
- Employees: ~100
Kernel's flagship product is Flow, a non-invasive neuroimaging device based on functional near-infrared spectroscopy (fNIRS). Flow measures brain activity by detecting changes in blood oxygenation using near-infrared light.
Key Features:
- Non-invasive: No surgery required - wearable headset
- Portable: Can be used in various settings
- Continuous Monitoring: Real-time brain activity tracking
- High Spatial Resolution: Better than standard EEG
- Cognitive Metrics: Measures attention, focus, and cognitive load
Kernel Mind is the company's AI-powered software platform that analyzes neural data from Flow devices, providing insights into cognitive states and brain health.
Capabilities:
- Cognitive state classification
- Mental health monitoring
- Focus and attention metrics
- Brain age estimation
- Neurodegeneration screening
| Program |
Application |
Stage |
Status |
| Flow |
Cognitive monitoring |
Commercial |
Available |
| Flow |
Clinical research |
Launched |
Active |
| Mind |
AI analytics |
Beta |
Testing |
| Next-gen |
Medical devices |
Development |
Preclinical |
- Cognitive Performance: Measuring attention and focus in real-time
- Research: Neuroscience research and clinical trials
- Mental Health: Monitoring cognitive biomarkers
- Brain Health: Early detection of cognitive decline
- Neurodegeneration Screening: Early detection of Alzheimer's and Parkinson's
- Stroke Rehabilitation: Monitoring recovery progress
- ADHD Assessment: Objective cognitive testing
- Brain-Computer Interfaces: Non-invasive control of devices
Kernel has raised over $110 million in total funding:
- Series A: $21 million (2017)
- Series B: $53 million (2019)
- Series C: $40 million (2021)
- Backed by: General Catalyst, Khosla Ventures, Thrive Capital
¶ Competitive Landscape
Kernel competes in the non-invasive BCI space with:
- EMOTIV
- g.tec
- NextMind
- NeuroSky
- Safety: No surgical risks
- Accessibility: Consumer-friendly wearable
- Cost: Lower than implantable devices
- Adoption: Easier mainstream adoption
- Signal Quality: Lower resolution than invasive approaches
- Spatial Resolution: Limited to surface measurements
- Motion Artifact: Sensitive to movement
¶ Research and Publications
Kernel collaborates with leading research institutions and has published papers on:
- Non-invasive neural signal processing
- Cognitive state classification algorithms
- Brain-computer interface applications
- FDA: Class II medical device clearance for Flow
- Research Use: Available for clinical research
- Consumer: Direct-to-consumer availability
Kernel's technology is relevant for neurodegenerative disease research and monitoring:
- Alzheimer's Disease: Brain age estimation and cognitive decline detection
- Parkinson's Disease: Movement-related cognitive monitoring
- Stroke Recovery: Rehabilitation progress tracking
- General Brain Health: Regular cognitive assessments
The non-invasive, wearable nature of Kernel Flow makes it suitable for:
- Long-term monitoring of brain health
- Early detection of cognitive changes
- Clinical trials requiring cognitive metrics
- Home-based brain health assessment